Invention Grant
US08815896B2 1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-B]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
有权
1-（5-叔丁基-2-苯基-2H-吡唑-3-基）-3- [2-氟-4-（1-甲基-2-氧代-2,3-二氢-1H-咪唑并[ 4,5-B]吡啶-7-基氧基） - 苯基] - 脲及其相关化合物及其在治疗中的用途
![1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-B]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy](/docs/US/2014-08-26/US08815896B2/abs.jpg.600x600.jpg)
- Patent Title: 1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-B]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
- Patent Title (中): 1-（5-叔丁基-2-苯基-2H-吡唑-3-基）-3- [2-氟-4-（1-甲基-2-氧代-2,3-二氢-1H-咪唑并[ 4,5-B]吡啶-7-基氧基） - 苯基] - 脲及其相关化合物及其在治疗中的用途
-
Application No.: US13520613Application Date: 2011-01-27
-
Publication No.: US08815896B2Publication Date: 2014-08-26
- Inventor: Caroline Springer , Ion Niculescu-Duvaz , Richard Marais , Dan Niculescu-Duvaz , Alfonso Zambon , Delphine Menard
- Applicant: Caroline Springer , Ion Niculescu-Duvaz , Richard Marais , Dan Niculescu-Duvaz , Alfonso Zambon , Delphine Menard
- Applicant Address: GB London GB London
- Assignee: The Institute of Cancer Research: Royal Cancer Hospital,Cancer Research Technology Limited
- Current Assignee: The Institute of Cancer Research: Royal Cancer Hospital,Cancer Research Technology Limited
- Current Assignee Address: GB London GB London
- Agency: Clark & Elbing LLP
- International Application: PCT/GB2011/000106 WO 20110127
- International Announcement: WO2011/092469 WO 20110804
- Main IPC: C07D401/02
- IPC: C07D401/02 ; A61K31/4353
![1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-B]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy](/abs-image/US/2014/08/26/US08815896B2/abs.jpg.150x150.jpg)
Abstract:
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain compounds of the following formula (I) (for convenience, collectively referred to herein as “IP compounds”), which, inter alia, are useful in the treatment of cancer, e.g., cancer characterized by (e.g., driven by) mutant RAS (“mutant RAS cancer”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions in the treatment of cancer, e.g., mutant RAS cancer.
Public/Granted literature
Information query
